3 Cancer in bones can be either primary (initiated in the bones) or secondary (has spread to the bones) in nature. In primary bone cancer, osteosarcoma can affect any bone in the skeleton, though the femur, tibia and humerus are most commonly affected. Osteosarcoma accounts for about 3% of cancer in children, especially during early adolescence when bone growth is at its peak (1). Ewing's sarcoma affects mainly teenagers and has an incidence of 34% among all bone cancer. It appears mainly in the pelvis, thigh and shin areas, although this type of tumour can also occur in soft tissues (soft-tissue sarcoma) (2). Rare forms of bone cancer account for the remaining 6% of bone cancer in children (3). Other primary bone cancer that affect mainly adults over 40 years old, are chondrosarcoma in hips, legs, arms and shoulders; several variations of spindle-cell sarcoma; and chordoma in lungs, nearby bones, lymph nodes, liver and skin. Secondary cancer can arise from primary tumours spreading to other tissues and the most prevalent tumours resulting from secondary bone cancer are those of the prostate, breast, lung, kidney and thyroid.
Survival rate after treatment depends highly on a patient's age at the time of diagnosis, and the stage and type of bone cancer. In teenagers with Ewing's sarcoma, survival rate after treatment ranges from 20 to 70% over 5 years, but is dependent on the site and size of the tumour (4-7). Treatment generally involves some type of surgery, and the stage of the cancer will determine which type of surgery will be used. It can vary from removing only the area affected in the bone to amputation of the limb. Further treatment can include radiotherapy and chemotherapy (8-10). Osteosarcomas can be treated with doxorubicin (a DNA intercalator), methotrexate (an antimetabolite) and cisplatin (a DNA alkylator). Dibenzoyl-methane derivatives (DBMD) (1; Figure 1 ) have been found in green tea leaves from Camellia sinensis and have been used in traditional medicine to treat several conditions, ranging from infection to rheumatic diseases, and as antioxidants. Their biological activity has not been completely elucidated, but studies in other cell lines indicate activities in p53, retinoblastoma, and mitochondria (17) (18) (19) (20) .
Generation of DBMD derivatives. We employed the improved Baker-Venkatarman arrangement (21), (Figure 2 ) to produce five dibenzoyl-methane derivatives: 2',4'-dihydroxy-dibenzoyl-methane (1), 2'-hydroxy-4'amino-dibenzoyl-methane (2) , 2',4'-dihydroxy3''methoxy-dibenzoyl-methane (3), and 2',4'-dihydroxy4''methoxydibenzoyl-methane (4). Thionylation of 2',4'-dihydroxy-dibenzoyl-methane produced 2',4'-dihydroxy-dithiodibenzoyl-methane (DBM-S, 5), (Figure 3 ).
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This article describes the development a novel molecule, 2', 4'dihydroxydithiondibenzoyl-methane and derivatives thereof and highly promising results obtained for cell viability in applying it against hepatic, colon, lung and osteoblasts cancer cell lines with subsequent in-depth studies in osteoblasts. 
Materials and Methods

Materials
Results and Discussion
Chemical synthesis. A new family of dibenzoyl-methane derivatives were synthesised as a one-pot reaction, in which an acylated phenol ester is formed from the reaction of a substituted acetophenone with benzyl chloride to yield a phenol ester, which then underwent a base-induced Baker-Venkatarman rearrangement to yield the wanted aromatic1,3-diketone. The thionylation of the 1,3-diketone of 2',4'-dihydroxy-dithiodibenzoyl-methane was performed using Lawesson's reagent. The compounds were purified using flash chromatography and then fully characterised (accurate MS, NMR and IR). The two carbonyl oxygens on the dibenzoyl-methane derivatives are known to undergo hydrogen bonding; this was observed in the proton NMR at higher than 10 ppm. All the starting materials are very economic hence the compounds were produced at a reduced cost, which is important when producing larger quantities for therapeutic purposes.
Biological activity. Saos2 (osteogenic sarcoma) is a bone cancer cell line derived from the primary osteosarcoma of an 11-year-old Caucasian girl. This cancer cell line possesses several osteoblastic features that make it extremely useful as a permanent line of human osteoblast-like cells for drug discovery and as a source of bone-related molecules (24) . We tested all five compounds on HepG2 (childhood liver cancer), HCT116 (adult colonic cancer), A549 (adult lung cancer) (and Saos2
(childhood osteoclast) cell line for 72 h (Table I) Apoptosis is a form of programmed cell death and is caspase-dependant, which is a safeguard mechanism protecting the organism while sacrificing the individual cell. Some drugs, such as doxorubicin and dactinomycin, are activators of the caspase pathway; caspase activation can appear in the very early stages, and sometimes this can be mistaken for necrosis (25) . However, other pathways of cell death are also possible in which caspases are not activated. These can include:
autophagy, paraptosis, mitotic catastrophe, and the descriptive model of apoptosislike and necrosis (26, 27) . Drugs with cytotoxic properties can trigger necrosis as death stimulus, with features such as disrupted cell membrane, destruction of organelles, swelling and then shrinking of the cell, and with the toxic waste being dispersed within the surrounding cells (28, 29) . These caspase-independent mechanisms can be produced by reactive oxygen species produced by external stimuli in the mitochondria (30) . This mechanism can be activated by molecules interacting with the T-cell/interferon/Toll-like/TNF superfamily receptors (31) and various anticancer molecules such as ionomycin (32) and catechins from green tea,
.
In a bid to identify a mode of action of our molecules, we employed the ApoToxGlo® (Promega) assay for assessing the mode of action. The caspase assay is composed of a substrate (proluminescent caspase-3/7 DEVD-aminoluciferin)
which is cleaved and the free aminoluciferin is reacted by the luciferase, producing a luminescent signal proportional to the caspase-3/7 activity (34). We tested DBM-S at 5, 10 and 20 µM for 24, 48 and 72 h and normalised the data to those of the vehicle control DMSO. The results indicate DBM-S reduced caspase activity steadily as the concentration used increased (Table II) . At an exposure of 24 h, the caspase activity was reduced by between 30-40%, at 48 hours it was reduced to around 50% and for a longer exposure of 72 h the activity was similar to that of the 1-day exposure as the level of activity was around 60%.
Cell division is regulated in an elaborate fashion to coordinate cell growth with 
Conclusion
Treating cancer in children aggressively is the best option for continued health, despite the risk that side-effects can arise years later. Sometimes sequelae from surgery can also diminish subsequent quality of life. Producing new selective and effective anticancer agents has become a goal for many laboratories which are now focusing their resources in this direction to achieve that aim. Here we used classic organic reactions to produce a family of dibenzoyl-methane derivatives with promising anticancer activities. Using established organic methods, we very cheaply produced five compounds that were tested for anticancer activity on different cell lines including hepatic, colon, lung and osteoblast cancer. Although all compounds showed some degree of activity against the cancer cell lines, DBM-S produced the most promising and interesting results. This novel compound, tested on different types of cancer cells, was shown to be very selective for osteoblasts, which could lead to the deduction that this compound would produce fewer gastrointestinal side-effects; this property can be exploited in formulation studies. It is possible that primary necrosis is the mechanism inducing cell death of Saos2 cells, however, sub-G1 cell accumulation indicates DNAse activation, which is considered a feature of apoptosis and this could be a very early stage in a multi-pathway activity. G1 arrest of Saos2 cells also indicates a block in cell-cycle progression consistent with inhibition of CDKs as a mechanism of action. Although more work will follow, this novel thionylated compound based on dibenzoyl-methane opens the possibility of studies for combination therapy in order to achieve less toxic side-effects during the treatment of bone cancer.
